Fundraising FoxThird Kind Venture Capital — 2021 Investments
6 investments dated 2021 · listed companies and verified rows first · show all
Envisagenics uses AI-driven analysis of RNA splicing to discover novel drug targets for immuno-oncology and neurodegenerative diseases.
AI & Machine LearningBiotechMedical DevicesNew York, US
Martin Akerman, PhD(CEO & Co-founder)Martin Akerman(Founder)inMaria Luisa Pineda(Founder)in
Co-investorsDolby Family VenturesDynamk CapitalHAWKTAILM12 (Microsoft's Venture Fund)Madrona Venture GroupRed Cell Incubation
Pickle builds hardware and software products that track user context and preferences to enable AI assistants to act proactively rather than reactively, including AR glasses and a web-based chat application.
AI & Machine LearningConsumerHardwareSan Francisco, US
Daniel Park(CEO)inSanio Jung(Founder)inEmmett Kim(Founder)inHojin Yu(Founder)inBirch Eve(Founder)Brian McMahon(Founder)
Co-investorsEight CapitalPioneerY CombinatorBass InvestmentBIP VenturesBoxGroup+10 more
Pickle is a peer-to-peer fashion rental marketplace based in NYC that lets users rent, lend, and resell clothing and accessories from each other's closets.
Julia O'Mara(Founder)Brian McMahon(Founder)in
Co-investorsCraft VenturesFirstMark CapitalFJ LabsTamarak CapitalBurst CapitalHyperplane Venture Capital+4 more
Software platform to improve drug discovery
AI & Machine LearningBiotechDeep TechNew York, US
David William Rooklin(Executive Officer, Director)Haotian Li(Director)
Co-investorsCollaborative FundHAWKTAILNotation CapitalAcequia Capital (AceCap)Preface VenturesRefactor Capital+1 more
Supergreat operated an online community platform focused on beauty and product reviews; the service has since wound down and directs its community to Whatnot.
ConsumerE-commerceSocial
Co-investorsShrug CapitalTq Ventures LlcArriveBenchmarkGreenoaksK5 Global+2 more
Other
Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.